![](https://static.biospace.com/dims4/default/33807f4/2147483647/strip/true/crop/997x561+436+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F03%2F64%2Fc4bd363e42a9abd3c1c342e7cafb%2Fistock-1421916191.jpg)
Big Pharma Appears to Be Unfazed by IRA Drug Price Negotiations
The second-quarter 2024 biopharma earnings season is upon us. Johnson & Johnson and Novartis kicked off the parade of Q2 financial results last week, and this week AbbVie, AstraZeneca, Roche and Sanofi joined the litany of announcements as well as …